Boehringer, Priaxon extend 86M euro cancer discovery pact; Blueprint names Sanofi vet as new CSO;

@FierceBiotech: Is Vertex as far behind in the oral hep C race as one might think? Maybe not. More | Follow @FierceBiotech

@JohnCFierce: Novo's new research center in Seattle will combine basic research/FIH studies for Type 1 diabetes. About 20 staffers. Release | Follow @JohnCFierce

@RyanMFierce: Ipsen has handed back rights to a Parkinson's drug to Santhera ($SANN), as Ipsen changes focus to late-stage contenders. Story | Follow @RyanMFierce

@MarkHFierce: B.U. has found some genetic triggers behind the onset of menopause. Info could help treat age-related diseases. Release | Follow @MarkHFierce

> Two years after striking their original partnership, Boehringer Ingelheim and Germany's Priaxon have extended their cancer drug discovery partnership, which entails 86 million euros in potential milestones. Release

> Blueprint Medicines has recruited Sanofi's ($SNY) oncology drug discovery chief as its new chief scientific officer. Christoph Lengauer will be in charge of the biotech's research efforts on personalized cancer drugs. Release

> New research indicates that the prostate-shrinking drug dutasteride could slow or even stop prostate cancer at an early stage of development, offering a therapeutic approach to replace surgery and radiation. Story

> Germany's immatics says it gained positive mid-stage data for an experimental oncology vaccine targeting colorectal cancer. Release

> Oncolytics Biotech announced C$15 million in bought deal financing. Release

> Michael Fonstein, Ph.D., has stepped down from his position as CEO of Cleveland Biolabs. Fonstein will be president of CBLI with a primary focus on advancing the CBLB502 program for acute radiation syndrome while Yakov Kogan, Ph.D., MBA, has been named interim CEO. Release

Pharma News

@FiercePharma: Litigation, recalls haunt J&J's Q4 earnings, and 2012 forecasts fall short of analyst estimates--Bloomberg. Report | Follow @FiercePharma

> Did Stiefel undervalue employee shares before GSK buyout? More

> Genzyme wins key FDA approval for new plant. Story

> Little 'oomph' in J&J's results as forecasts fall short. Article

> Publicist quits over Deen's tie-up with Novo. Item

Pharma Manufacturing News

> Pakistan suspects heart drug contamination in patient deaths, seals plant. News

> Law firm brings logistics savvy to Miami. Article

> Roche workers protest use of contractors. News

> Pfizer revels in massive Prevnar vax job. Interview

> Balance adaptability, planning in supply chain, Tompkins advises. Item

> GSK's CEO Witty wants U.K. focus on manufacturing. More

Research News

> Obama seeks to beat Alzheimer's by 2025. Article

> Eat your vegetables to fight colon cancer, plus 2 other discoveries. More

> Genetic analysis yields hypertension clue. Story

> U.K. team finds gene link for esophageal cancer. News

> Targeting NKp46 boosts immune response, Innate Pharma believes. Item

And Finally... Scientists in the U.K. have developed "magnetic" soap, which one day could be used to clean up some toxic spills. Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.